cbdMD, Inc. (YCBD)
Company Description
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products.
The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals.
Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids.
The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand.
It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States.
The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019.
cbdMD, Inc. is headquartered in Charlotte, North Carolina.
Country | United States |
Founded | 2015 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 52 |
CEO | T. Ronan Kennedy |
Contact Details
Address: 8845 Red Oak Boulevard Charlotte, North Carolina 28217 United States | |
Phone | 704-445-3060 |
Website | cbdmd.com |
Stock Details
Ticker Symbol | YCBD |
Exchange | NYSEAMERICAN |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0001644903 |
CUSIP Number | 12482W101 |
ISIN Number | US12482W3097 |
Employer ID | 47-3414576 |
SIC Code | 2844 |
Key Executives
Name | Position |
---|---|
T. Ronan Kennedy | Interim Chief Executive Officer, Principal Executive Officer, Chief Financial Officer, Secretary and Treasurer |
Dr. Sibyl Swift Ph.D. | CSO, Vice President of Regulatory Affairs and Director |
Zeb Booker | Chief Technology Officer |
John Weston | Director of Investor Relations |
Lance Blundell | General Counsel |
Robert Pettway | Director of Public Relations |
Francisco Mangual | Senior Vice President of Sales |
Shannon Charles | Chief Marketing Officer |
David Johnson | Senior Vice President of Business Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 424B4 | Prospectus |
Mar 26, 2024 | EFFECT | Notice of Effectiveness |
Mar 19, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Mar 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 18, 2024 | 8-K | Current Report |
Mar 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 1, 2024 | 8-K | Current Report |
Feb 16, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Feb 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Feb 14, 2024 | DEF 14A | Other definitive proxy statements |